LAVA Therapeutics NV LVTX.OQ LVTX.O is expected to show a fall in quarterly revenue when it reports results on November 25 (estimated) for the period ending September 30 2024
LSEG's mean analyst estimate for LAVA Therapeutics NV is for a loss of 33 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for LAVA Therapeutics NV is $6.00, above its last closing price of $1.48.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -0.37 | -0.36 | -0.31 | Beat | 13.9 |
Mar. 31 2024 | -0.11 | -0.12 | -0.02 | Beat | 84 |
Dec. 31 2023 | 0.33 | -0.12 | -0.24 | Missed | -92 |
Sep. 30 2023 | -0.49 | -0.49 | -0.34 | Beat | 30.6 |
Jun. 30 2023 | -0.47 | -0.47 | -0.48 | Missed | -1.4 |
Mar. 31 2023 | -0.52 | -0.52 | -0.53 | Missed | -1.9 |
Dec. 31 2022 | -0.63 | -0.57 | Beat | 10.1 | |
Sep. 30 2022 | 0.00 | -0.14 | 0.04 | Beat | 128.7 |
This summary was machine generated November 22 at 13:56 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。